Drug Search Results
More Filters [+]

AD-2081

Alternative Names: ad-2081, ad2081, ad 2081
Latest Update: 2023-07-21
Latest Update Note: Clinical Trial Update

Product Description

Addpharma is developing AD-2081 as a treatment for Androgenetic Alopecia. (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT04825561)

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Addpharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for AD-2081

Countries in Clinic: Korea

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Alopecia Areata

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

AD-208P3

P3

Completed

Alopecia Areata

2023-01-09

45%

AD-208P3

P3

Completed

Alopecia Areata

2023-01-09

45%

Recent News Events

Date

Type

Title